XY0206

DRUG4 trials

Sponsors

Shijiazhuang Yiling Pharmaceutical Co. Ltd

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia With FLT3/ITD MutationAdvanced or Metastatic Solid Tumours

Phase 1

A Study of XY0206 in Subjects With Advanced or Metastatic Solid Tumours

Shijiazhuang Yiling Pharmaceutical Co. LtdAdvanced or Metastatic Solid Tumours

Start: 2018-12-19End: 2020-12-31Target: 34Updated: 2020-08-21

A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia

Shijiazhuang Yiling Pharmaceutical Co. LtdAcute Myeloid Leukemia

Start: 2020-09-15End: 2024-02-29Target: 60Updated: 2023-05-18

A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants

RecruitingNCT07162116

Shijiazhuang Yiling Pharmaceutical Co. LtdAcute Myeloid Leukemia With FLT3/ITD Mutation

Start: 2025-07-06End: 2026-05-31Target: 45Updated: 2025-09-09

Phase 3

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Not yet recruitingNCT05876832

Shijiazhuang Yiling Pharmaceutical Co. LtdAcute Myeloid Leukemia With FLT3/ITD Mutation

Start: 2023-06-15End: 2027-07-01Target: 312Updated: 2023-05-26

Related Papers

A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood2023-11-021 citations